Richard Segal

Partner
rsegal@cooley.com
Full contact info

I bring experience, practicality, and a lot of energy to make transformative capital markets transactions smooth, painless and fun.

About Richard

Rich represents high-growth companies, investment banks and institutional investors in equity and debt offerings, with a focus on the technology, life sciences and consumer/retail sectors. Rich also counsels public companies on Securities and Exchange Commission compliance and reporting, and he advises private companies on a wide range of corporate and securities matters.

View full bio

Passions

Big mountains

Deep snow

Experience

Abivax Announces $235.8 Million IPO

Abivax Announces $235.8 Million IPO

October 20, 2023

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Read more

Related contacts

Div Gupta
Partner, New York
Marc Recht
Partner, Boston
Ryan Sansom
Partner, Boston
Denny Won
Partner, San Francisco
Aaron Pomeroy
Partner, Colorado
Richard Segal
Partner, New York
Nyron J. Persaud
Partner, New York
Madhuri Roy
Partner, Palo Alto
Courtney Thorne
Partner, Boston
Elizabeth Anne Wright
Of Counsel, Brussels
Xander Lee
Partner, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Stephanie Gentile
Partner, New York
Kevin King
Partner, Washington, DC
Katie Kazem
Partner, Reston
Natasha Leskovsek
Of Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Randy Sabett
Special Counsel, Washington, DC
Jennifer Shanley
Special Counsel, New York
Reid Hooper
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Minkyu Park
Associate, New York
Jesse Schulman
Associate, Washington, DC
Barry Kuang
Associate, Boston
Olivia Creser
Associate, New York
Peter A. Haddad
Associate, San Diego
Samuel Paullin
Associate, Chicago
Evan Leitner
Associate, New York
Rick Jantz
Associate, Los Angeles Santa Monica
Cara Buchicchio
Associate, New York
Jason Valentine
Associate, Washington, DC
Jessica Koffel
Associate, Brussels
Mor Agam
Associate, New York
Cathy Rude
Paralegal Specialist, Boston

Related Practices & Industries

Capital Markets
Life Sciences
Biotechnology
Public Companies
Healthcare
CFIUS
Tax
Intellectual Property
Cyber/Data/Privacy
Commercial Litigation

Immunology Company argenx Announces $1.27 Billion Global Offering

Immunology Company argenx Announces $1.27 Billion Global Offering

July 26, 2023

Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.

Read more

Related contacts

Richard Segal
Partner, New York
Div Gupta
Partner, New York
Darah Protas
Partner, Washington, DC
Charles York
Associate, New York
Katie Lapidus
Associate, Washington, DC
Carley Cruea
Associate, Washington, DC
Bill Christiansen
Partner, Seattle
Phil Mitchell
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Jennifer Shanley
Special Counsel, New York
Dr. Tian Yong Zheng
Patent Agent, Seattle

Related Practices & Industries

Capital Markets
Life Sciences
Intellectual Property
Healthcare

Liminal BioSciences to Be Acquired by Structured Alpha

Liminal BioSciences to Be Acquired by Structured Alpha

July 13, 2023

Cooley advised Liminal BioSciences, a Canada-based development-stage biopharmaceutical companylisted on Nasdaq, on its all-cash cross-border sale to Structured Alpha, a fund managed by Thomvest Asset Management

Read more

Related contacts

Kevin Cooper
Partner, New York
Richard Segal
Partner, New York
Christine Tse
Associate, New York

Related Practices & Industries

Mergers and Acquisitions
Public Companies
Life Sciences

Prelude Therapeutics – $100 Million Follow-on Offering

Prelude Therapeutics – $100 Million Follow-on Offering

May 18, 2023

Cooley advised the underwriters in Prelude Therapeutics’ $100 million follow-on offering. Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Lawyers Richard Segal, Div Gupta, Darah Protas, Sam Paullin and Katie Lapidus led the Cooley team.

Related contacts

Richard Segal
Partner, New York
Virat Gupta
Associate, Washington, DC
Darah Protas
Partner, Washington, DC
Samuel Paullin
Associate, Chicago
Katie Lapidus
Associate, Washington, DC

Related Practices & Industries

Capital Markets
Life Sciences

Karuna Therapeutics – $460 Million Follow-on Offering

Karuna Therapeutics – $460 Million Follow-on Offering

March 21, 2023

Cooley advised the underwriters in Karuna Therapeutics’ $460 million follow-on offering. Karuna is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Goldman Sachs & Co., JP Morgan, Morgan Stanley, Stifel, and Guggenheim Securities acted as joint book-running managers for the offering. Partners Richard Segal, Div Gupta and Jean Park led the Cooley team.

Related contacts

Richard Segal
Partner, New York
Div Gupta
Partner, New York
Jean Park
Partner, New York
Darah Protas
Partner, Washington, DC
Katie Lapidus
Associate, Washington, DC
Quay Strozier
Associate, Washington, DC
Charles York
Associate, New York

Related Practices & Industries

Capital Markets
Life Sciences
View more

Admissions & credentials

New York

Massachusetts

Rankings & accolades

Chambers USA: Capital Markets: Debt & Equity – Eastern United States - Nationwide (2023)

Chambers USA: Capital Markets – Massachusetts (2020 – 2022)

The Legal 500 US: Next Gen Partner for Capital Markets: Equity Offerings (2021 – 2023)

Massachusetts Super Lawyers: Rising Star – Securities & Corporate Finance (2013 – 2022)

He knows how to get deals done, has great judgment, and he understands the client really well.

Chambers USA